* Annovis Bio Inc ANVS.N ANVS.K is expected to show no
change
in quarterly revenue when it reports results on August 13
(estimated) for the period ending June 30 2024
*
* LSEG's mean analyst estimate for Annovis Bio Inc is for a
loss
of 50 cents per share.
* The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 3 "strong buy" or "buy," 2
"hold" and no "sell" or "strong sell."
* The mean earnings estimate of analysts was unchanged in
the last
three months.
* Wall Street's median 12-month price target for Annovis Bio
Inc
is $28.00, above its last closing price of $8.25.
Previous quarterly performance (using preferred earnings measure
in US dollars).
QUARTER STARMINESM LSEG IBES ACTUAL BEAT, SURPRI
ENDING ARTESTIMAT ESTIMATE MET, SE %
E® MISSED
Mar. 31 2024 -0.84 -0.80 -0.10 Beat 87.5
Dec. 31 2024 -1.39 -1.30 -2.24 Missed -71.7
Jan. 1 0001 -1.06 -1.09 -1.63 Missed -49.5
Jun. 30 2023 -1.11 -1.14 -1.07 Beat 6.3
Mar. -0.33 -0.33 -1.19 Missed -256.3
31 2023
Dec. 31 2022 -1.05 -1.05 -0.38 Beat 63.9
Sep. 30 2022 -1.02 -1.01 -0.93 Beat 8.2
Jun. 30 2022 -0.65 -0.64 -1.07 Missed -65.9
This summary was machine generated August 9 at 17:59 GMT. All
figures in US dollars unless otherwise stated. (For questions
concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com)